A Second Look at the Impact of TERTp Mutation on Meningioma Grade

Cutting Edge Technologies Unlocking Barrett's Esophagus Clonal Cell States

cutting-edge-technologies-unlocking-barrett-s-esophagus-clonal-cell-states [https://support.doctorpodcasting.com/media/k2/items/cache/936e37ccf41d9d9d72593f27e57368ec_S.jpg]https://support.doctorpodcasting.com/media/k2/items/cache/936e37ccf41d9d9d72593f27e57368ec_Generic.jpg In this episode, Dr. Sydney Shaffer shares her expertise on cutting-edge technologies, including single-cell and spatial transcriptomics, and their significance for understanding cancer biology. The guest discusses these tools in the context of her recent Nature Communications publication (https://doi.org/10.1038/s41467-025-66302-w [https://doi.org/10.1038/s41467-025-66302-w]), which provides a single-cell view of cell dynamics in Barrett’s esophagus and links cell states along the disease trajectory from its origin to cancer. #Barrett's #Esophagus #SpatialTranscriptomics #Dysplasia

Revolutionizing CNS Tumor Diagnostics: Intraoperative Methylation Profiling!

revolutionizing-cns-tumor-diagnostics-intraoperative-methylation-profiling [https://support.doctorpodcasting.com/media/k2/items/cache/78a510cbb54be65b58be77784be4b7d1_S.jpg]https://support.doctorpodcasting.com/media/k2/items/cache/78a510cbb54be65b58be77784be4b7d1_Generic.jpg Join Dr. George Netto as he discusses with Professor Felix Sahm, an international expert from Heidelberg University, his team's innovative multi-center study on intraoperative molecular profiling of central nervous system tumors (CNS). Learn how rapid methylation profiling could change the landscape of diagnostics and management of brain neoplasms. Don't miss this enlightening discussion! #Neuropathology #CNS #BrainTumors #MolecularProfiling #MethylationProfiling #PrecisionMedicine #ArtificialIntelligence

A Second Look at the Impact of TERTp Mutation on Meningioma Grade

a-second-look-at-the-impact-of-tertp-mutation-on-meningioma-grade [https://support.doctorpodcasting.com/media/k2/items/cache/dcbc1b75f7995797e96e7860ba526e0d_S.jpg]https://support.doctorpodcasting.com/media/k2/items/cache/dcbc1b75f7995797e96e7860ba526e0d_Generic.jpg Join Dr. George Netto and Dr. Matija Snuderl of Langone Health at NY University as they discuss the significance of TERT promoter mutations in meningiomas and their implications for patient prognosis. This conversation sheds light on the need for reevaluation of molecular biomarkers in the grading of Meningiomas. #Meningioma #MolecularDiagnostics #TERTPromoter #Pathology #CancerResearch #TumorGrade

AI-Driven Biomarkers for Antibody-Drug Conjugates (ADC)

ai-driven-biomarkers-for-antibody-drug-conjugates-adc [https://support.doctorpodcasting.com/media/k2/items/cache/65b0c750b52b0ff3fb9034a018a33d50_S.jpg]https://support.doctorpodcasting.com/media/k2/items/cache/65b0c750b52b0ff3fb9034a018a33d50_Generic.jpg In this episode, I discuss with Dr. Salgado, Co-Chair of the International Immuno-Oncology Biomarkers Working Group, his editorial (https://doi.org/10.1016/j.ccell.2025.03.020 [https://doi.org/10.1016/j.ccell.2025.03.020]) on the recent Cancer Cell study by Ding Ma et al, presenting a predictive AI model for HER2-targeting ADC efficacy, incorporating immune system components, hormone receptor status, clinical staging, and HER2+ cell proportion.  #ImmunoOncology #HER2Biomarker #AntibodyDrugConjugates

Introduction to Precision Pathology Podcast

introduction-to-precision-pathology-podcast [https://support.doctorpodcasting.com/media/k2/items/cache/9deff925a39317506d5d73f871993050_S.jpg]https://support.doctorpodcasting.com/media/k2/items/cache/9deff925a39317506d5d73f871993050_Generic.jpg Introducing P³ Podcast Welcome to P³, our new podcast series on Precision Pathology, created and hosted by Dr. George J. Netto, the Simon Flexner Professor and  Chair of Pathology and Laboratory Medicine at the University of Pennsylvania in Philadelphia, PA. In each episode, Dr. Netto will share his perspective on the latest discoveries in precision medicine through informal conversations with accomplished authors and thought leaders from around the world. These dynamic discussions are designed to keep you informed about the most critical publications from high-impact journals. Topics will cover a wide range of disruptive technological advances in diagnostics, prognostics, and predictors of therapeutic response—from digital and computational pathology to spatial and single-cell omics, cell-free nucleic acid assays, and the latest in cellular therapeutics. We hope you’ll enjoy listening and watching and find the conversations both informative and stimulating. We welcome your thoughts and feedback. Please feel free to connect by email (george.netto@pennmedicine.upenn.edu) or at Dr. Netto’s LinkedIn or Substack.